MX384198B - Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. - Google Patents
Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.Info
- Publication number
- MX384198B MX384198B MX2017007826A MX2017007826A MX384198B MX 384198 B MX384198 B MX 384198B MX 2017007826 A MX2017007826 A MX 2017007826A MX 2017007826 A MX2017007826 A MX 2017007826A MX 384198 B MX384198 B MX 384198B
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- binding
- relates
- binding domains
- vector
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una molécula de unión biespecífica que comprende tres dominios de unión, en donde un primer y/o un segundo dominio de unión son capaces de unirse al antígeno 5T4 extracelular y el o los dominios de unión restantes es/son capaces de unirse al complejo receptor CD3 en células T. Además, la invención se refiere a una secuencia de ácido nucleico que codifica para una proteína de fusión, a un vector que comprende la secuencia de ácido nucleico y a una célula hospedera transformada o transfectada con el vector. Más aún, la invención se refiere a un proceso para la producción de la proteína de fusión de la invención, a un uso médico de la proteína de fusión y a un kit que comprende la proteína de fusión.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199493 | 2014-12-19 | ||
| PCT/EP2015/080795 WO2016097408A1 (en) | 2014-12-19 | 2015-12-21 | Fusion protein comprising three binding domains to 5t4 and cd3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007826A MX2017007826A (es) | 2018-02-13 |
| MX384198B true MX384198B (es) | 2025-03-14 |
Family
ID=52282472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007826A MX384198B (es) | 2014-12-19 | 2015-12-21 | Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10941207B2 (es) |
| EP (1) | EP3233917B1 (es) |
| JP (1) | JP6709003B2 (es) |
| KR (1) | KR102495820B1 (es) |
| CN (1) | CN107406509B (es) |
| AU (1) | AU2015366166B2 (es) |
| BR (1) | BR112017012910A2 (es) |
| CA (1) | CA2970986C (es) |
| ES (1) | ES2981736T3 (es) |
| GB (1) | GB2549632B (es) |
| MX (1) | MX384198B (es) |
| WO (1) | WO2016097408A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018054484A1 (en) | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| FI3582806T3 (fi) | 2017-02-20 | 2023-09-07 | Dragonfly Therapeutics Inc | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja |
| CN108690136B (zh) * | 2017-04-05 | 2022-09-20 | 凯惠科技发展(上海)有限公司 | 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用 |
| JP7164544B2 (ja) | 2017-04-11 | 2022-11-01 | インヒブルクス インコーポレイテッド | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 |
| CA3064567A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| US11365254B2 (en) | 2017-09-22 | 2022-06-21 | WuXi Biologics Ireland Limited | Bispecific CD3/CD19 polypeptide complexes |
| BR112020005676A2 (pt) | 2017-09-22 | 2020-10-20 | WuXi Biologics Ireland Limited | novos complexos polipeptídicos biespecíficos |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| CR20250348A (es) * | 2018-03-12 | 2025-09-23 | Genmab As | ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-463) |
| CN112218686A (zh) | 2018-04-11 | 2021-01-12 | 印希比股份有限公司 | 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| JP2022504802A (ja) * | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | ５ｔ４シングルドメイン抗体およびその治療組成物 |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
| EP4028424A1 (en) * | 2019-09-12 | 2022-07-20 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| EP4107190A4 (en) * | 2020-02-18 | 2024-03-20 | Nanjing GenScript Biotech Co., Ltd. | FUSION PROTEINS AND USES THEREOF |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| US20230220067A1 (en) * | 2020-06-05 | 2023-07-13 | The Johns Hopkins University | Humanized antibodies directed against kcnk9 |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| KR20240004837A (ko) * | 2021-05-04 | 2024-01-11 | 임뮤노라이즌 엘티디. | 항-5t4 항체 및 이의 용도 |
| IL316002A (en) | 2022-04-11 | 2024-11-01 | Regeneron Pharma | Compositions and methods for universal tumor cell killing |
| WO2024005204A1 (ja) * | 2022-06-30 | 2024-01-04 | 株式会社カイオム・バイオサイエンス | 融合タンパク質 |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
| KR20240139569A (ko) * | 2023-03-13 | 2024-09-23 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CN101490085A (zh) | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| CN103857699B (zh) * | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| EP2758438A1 (en) * | 2011-09-23 | 2014-07-30 | Amgen Research (Munich) GmbH | Bispecific binding molecules for 5t4 and cd3 |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
-
2015
- 2015-12-21 GB GB1709537.3A patent/GB2549632B/en active Active
- 2015-12-21 BR BR112017012910-8A patent/BR112017012910A2/pt not_active Application Discontinuation
- 2015-12-21 EP EP15817832.7A patent/EP3233917B1/en active Active
- 2015-12-21 US US15/536,121 patent/US10941207B2/en active Active
- 2015-12-21 ES ES15817832T patent/ES2981736T3/es active Active
- 2015-12-21 AU AU2015366166A patent/AU2015366166B2/en active Active
- 2015-12-21 CA CA2970986A patent/CA2970986C/en active Active
- 2015-12-21 JP JP2017532005A patent/JP6709003B2/ja active Active
- 2015-12-21 CN CN201580076505.9A patent/CN107406509B/zh active Active
- 2015-12-21 KR KR1020177018818A patent/KR102495820B1/ko active Active
- 2015-12-21 MX MX2017007826A patent/MX384198B/es unknown
- 2015-12-21 WO PCT/EP2015/080795 patent/WO2016097408A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018500025A (ja) | 2018-01-11 |
| JP6709003B2 (ja) | 2020-06-10 |
| KR102495820B1 (ko) | 2023-02-06 |
| AU2015366166A1 (en) | 2017-06-29 |
| KR20170094319A (ko) | 2017-08-17 |
| ES2981736T3 (es) | 2024-10-10 |
| EP3233917B1 (en) | 2024-04-17 |
| CN107406509A (zh) | 2017-11-28 |
| CA2970986A1 (en) | 2016-06-23 |
| CN107406509B (zh) | 2021-10-29 |
| AU2015366166B2 (en) | 2021-08-05 |
| US20170342160A1 (en) | 2017-11-30 |
| GB2549632B (en) | 2020-09-23 |
| US10941207B2 (en) | 2021-03-09 |
| BR112017012910A2 (pt) | 2018-02-06 |
| GB201709537D0 (en) | 2017-08-02 |
| GB2549632A (en) | 2017-10-25 |
| EP3233917A1 (en) | 2017-10-25 |
| WO2016097408A1 (en) | 2016-06-23 |
| MX2017007826A (es) | 2018-02-13 |
| CA2970986C (en) | 2021-10-26 |
| GB2549632A8 (en) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384198B (es) | Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. | |
| PH12018500157A1 (en) | Antibody constructs for flt3 and cd3 | |
| SA520411173B1 (ar) | Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137 | |
| JO3519B1 (ar) | تركيبات أجسام مضادة لأجل cdh19 و cd3 | |
| MX372679B (es) | Moleculas de union para bcma y cd3. | |
| PH12018500216A1 (en) | Antibody constructs for cd70 and cd3 | |
| MX2021008367A (es) | Constructos de anticuerpos para cdh19 y cd3. | |
| PH12018500241A1 (en) | Antibody constructs for dll3 and cd3 | |
| MX384418B (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido. | |
| MY185953A (en) | Bispecific antibody constructs binding egfrviii and cd3 | |
| MY190421A (en) | Bcma and cd3 bispecific t cell engaging antibody constructs | |
| MY195542A (en) | Psma and CD3 Bispecific T Cell Engaging Antibody Constructs | |
| MX2017001401A (es) | Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas. | |
| MX2017013348A (es) | Construcciones de anticuerpos biespecificos contra cdh3 y cd3. | |
| EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
| EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
| EA202092283A1 (ru) | Конструкции антител к cdh19 и cd3 |